Rhythm Biosciences onboards two top health experts
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Rhythm Biosciences Limited (ASX:RHY) has strengthened its management team by appointing two experienced health sector executives, including Glenn Gilbert as Chief Operating Officer.
Gilbert has held various roles at the ASX-listed Medical Developments International (ASX:MVP), most recently as head of sales and marketing with oversight of global product commercialisation. His eight years of experience at MVP included mergers and acquisitions, as well as IP management.
Prior to his tenure at MVP, Gilbert held leadership roles at CSL’s biotherapeutics arm, now known as Seqirus. He holds a Monash University Bachelor of Science qualification, as well as a Graduate Certificate in Corporate Management and a Masters of Business Administration.
RHY’s second appointment is Dr Joanne Boagas as General Manager – Commercial, who brings with her 14 years’ experience in the health and medical research fields, including a decade of experience in commercialising technologies, most recently working within medical research institutes to improve and develop research programs and commercialise early-stage technologies.
Boag is also a registered Australian patent and trademark attorney, and has spent more than five years in private practice at a specialist IP firm. She has a PhD in molecular biology from the University of Western Australia.
The two appointees join an experienced team, and will work closely with General Manager of the ColoSTAT product Craig Lewis, who has spent over a decade leading innovative projects within the complex biomedical device regulatory environment including as a consultant at Planet Innovation.
Lewis is named as an inventor on four granted patents and has a Bachelor of Engineering and a Bachelor of Science from the University of Melbourne.
Adding even more to the depth of expertise among the team, CEO Trevor Lockett has wide experience in multidisciplinary research including prostate cancer gene therapies and colorectal cancer prevention.
“Both Glenn and Joanne come with excellent pedigrees,” Lockett said.
“Their broad and relevant experience will be invaluable to the company as we move to commercialise our simple and effective test for early detection of colorectal cancer.”
The company remains on track to complete the cloning of its four mixed monoclonal antibody preparations by the end of June as a component of its broader objective to develop its own antibodies and target proteins to give it control of the supply, quality and cost of its key reagents.
However, the size of the market share RHY can secure remains to be seen at this stage, so if considering this stock for your portfolio, do your own research and seek professional financial advice.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
